Kurkin D V, Bakulin D A, Morkovin E I, Strygin A V, Gorbunova Ju V, Volotova E V, Robertus A I, Makarenko I E, Saparova V B, Drai R V, Petrov V I
Russian University of Medicine; Volgograd State Medical University.
Russian University of Medicine.
Probl Endokrinol (Mosk). 2024 Feb 28;70(1):91-99. doi: 10.14341/probl13312.
The progressive nature of type 2 diabetes mellitus leads to the need for insulin therapy in a significant proportion of patients. Very often start of insulin therapy in type 2 diabetes mellitus (T2DM) is associated with weight gain and a significant increase of hypoglycemia's risk. However, innovative options, such as fixed ratio combinations of glucagon-like peptide 1 receptor agonists (GLP-1RA) and basal insulin, minimize weight gain and hypoglycemia risks and allow a greater proportion of patients to achieve individual glycemic control goals without compromising safety parameters. This review includes a description of the randomized clinical trials, as well as the results of real clinical practice of the use of two currently existing fixed ration combinations of GLP-1RA and basal insulin - iDegLira and iGlarLixi.
2型糖尿病的进展特性导致相当一部分患者需要胰岛素治疗。2型糖尿病（T2DM）患者开始胰岛素治疗时常常伴有体重增加以及低血糖风险显著升高。然而，一些创新方案，如胰高血糖素样肽1受体激动剂（GLP-1RA）与基础胰岛素的固定比例复方制剂，可将体重增加和低血糖风险降至最低，并使更大比例的患者在不影响安全参数的情况下实现个体化血糖控制目标。本综述包括对随机临床试验的描述，以及目前两种现有的GLP-1RA与基础胰岛素固定比例复方制剂——德谷胰岛素利拉鲁肽和甘精胰岛素利司那肽在实际临床应用中的结果。
